
CHINA PHARMA HOLDINGS INC
CPHINYSE AMERICANTrading Snapshot
- Day Range
- $1.10 โ $1.12
- 52-Week Range
- $0.38 โ $19.19
- Volume
- $1.81B
- Avg Volume
- $2.25B
- Shares Outstanding
- 40.5M
- Next Earnings
- Sep 24, 2026
Fundamentals Snapshot
- Annual Revenue
- $4M
- Last Q Revenue
- $983,536
- P/E Ratio
- -1.4
- P/S Ratio
- 11.5x
- EPS (TTM)
- $-0.83
- Dividend Yield
- 0.00%
Why Investors Own CPHI
- โHigh-growth profile โ revenue up +45.0% YoY with expanding US Equity exposure.
- โHealthy economics โ 71% gross margin and 26% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About CHINA PHARMA HOLDINGS INC
China Pharma Holdings, Inc. (CPHI) specializes in the development, manufacturing, and marketing of both generic and branded pharmaceutical as well as biochemical products. The company primarily caters to hospitals and independent retailers throughout mainland China. Its comprehensive product portfolio encompasses diverse formulations, including powdered and liquid injectables, oral tablets, capsules, and cephalosporin-based oral solutions. CPHI's extensive range of medical solutions targets various health conditions. For neurological and cognitive health, it offers Cerebroprotein Hydrolysate injections to address memory decline and attention deficits, and Gastrodin injections for symptoms such as fatigue, lack of concentration, sleep disturbances, and traumatic brain syndromes. Cardiovascular and cerebrovascular treatments include Propylgallate and Ozagrel Sodium for conditions like cerebral thrombosis, coronary heart disease, and post-surgical recovery, as well as Alginic Sodium Diester injections targeting ischemic heart disease, cerebrovascular ailments, and hyperlipoproteinemia. Additionally, CPHI provides Bumetanide injections for edema management and Candesartan for hypertension. The company also produces a variety of anti-infective medications. These feature Roxithromycin dispersible tablets for throat infections (pharyngitis and tonsillitis), and Cefaclor dispersible tablets effective against conditions such as otitis media, lower respiratory tract infections, urinary tract infections, and skin/soft tissue infections. Other anti-infectives include Cefalexin capsules for acute tonsillitis, Andrographolide for sore throats stemming from upper respiratory tract infections, and Clarithromycin available in both granule and capsule forms. For pain and cold relief, CPHI offers sustained-release tablets containing Naproxen Sodium and Pseudoephedrine Hydrochloride. Furthermore, CPHI manufactures treatments for digestive disorders, including Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeprazole. The product lineup extends to Vitamin B6 injections, Granisetron Hydrochloride injections for alleviating nausea and vomiting induced by cancer therapies (radiotherapy and chemotherapy), and dietary supplements like Noni Enzyme. Complementing its medical offerings, the company also provides health-related products such as sanitizers and protective masks. The company distributes its offerings via a network of third-party distributors, augmented by its own 16 sales offices and a team of around 1,000 sales professionals. Established in 1993, China Pharma Holdings, Inc. maintains its headquarters in Haikou, located in the People's Republic of China.
Otter Score Breakdown
โAnalyst Price Target
โLatest News & Updates

Top movers analysis one hour before the close of the markets on 2026-07-22: top gainers and losers in today's session.
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Zhengye Biotechnology (NASDAQ:ZYBT) shares moved upwards by 24.0% to $1.71 during Wednesday's after-market session. The market value of their outstanding shares is at $135.0 million. Medpace Holdings

These stocks have an unusual volume in today's session
Unusual volume stocks in Wednesday's session

Top movers analysis in the middle of the day on 2026-07-22: top gainers and losers in today's session.
Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Gapping stocks in Wednesday's session
The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Advanced Biomed (NASDAQ:ADVB) shares moved upwards by 108.6% to $14.77 during Wednesday's regular session. The company's market cap stands at $11.5 million. Lakewood-Amedex (NASDAQ:LABT) shares moved